focus
Previous article：
How to save PrEP access — and even expand it
Next article： FDA panel to weigh approval of NurOwn, controversial ALS drug
Next article： FDA panel to weigh approval of NurOwn, controversial ALS drug
leisure time
focus
-
Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds
2025-09-30 00:44
-
In boost for rare disease push, AstraZeneca to buy Amolyt Pharma
2025-09-30 00:37
-
Why scientists need input from humanists on sensitive research
2025-09-29 23:52
-
Why scientists need input from humanists on sensitive research
2025-09-29 23:51 -
Ebola: Gilead Sciences antiviral shows promise as new treatment
2025-09-29 23:44
-
Ukraine and a new approach to mental health in war
2025-09-29 22:29